Half-Year 2022 Financial and Clinical Trials Update
HY 2022: Highlights
Roche
Business
Group sales growth of +5% driven by good performance of Pharmaceuticals and Diagnostics division
⚫ Pharma established products and new launches performing well; Diagnostics continuing with strong double-digit sales
Core operating profit up +9% and Core EPS growth +11% (including +6.1%p net accretion Novartis share repurchase and 3.5%p from Ultomiris
patent settlement)
Cash flow
•
Operating Free Cash Flow of CHF 9.8bn, +21% growth driven by strong operating results and movements in net working capital
.
Net debt higher by CHF 2.7bn vs. Dec 31st 2021
Net financial result
• Core net financial expense increased by CHF -370m driven by loss on equity securities
IFRS
•
Net income +12% driven by the operating results and lower intangible assets amortization
Growth rates at CER (Constant exchange Rates)
51View entire presentation